Anavex Life Sciences (Nasdaq: AVXL) trims Q2 loss, ends with $127.4M cash
Rhea-AI Filing Summary
Anavex Life Sciences Corp. reported preliminary results for its fiscal second quarter ended March 31, 2026 and provided a business update centered on lead candidate ANAVEX®2‑73 (blarcamesine) for early Alzheimer’s disease, Rett syndrome and Fragile X syndrome, highlighting a disciplined, data‑driven regulatory strategy and FDA engagement.
Preliminary cash and cash equivalents were $127.4 million as of March 31, 2026, up from $102.6 million as of September 30, 2025, and the company states it expects this balance to fund operations into mid‑to‑late fiscal 2028. For the quarter, general and administrative expenses were $2.3 million versus $2.6 million a year earlier, and research and development expenses were $4.2 million versus $9.9 million, primarily reflecting completion of the ANAVEX® 3‑71 schizophrenia trial and lower clinical manufacturing activity. Net loss narrowed to $5.3 million, or $0.06 per share, from $11.2 million, or $0.13 per share, on a weighted‑average 92,675,753 shares versus 85,073,769.
All figures are preliminary and subject to completion of financial closing procedures. The company also cites risks related to regaining compliance with Nasdaq Listing Rule 5250(c)(1) after a delayed Form 10‑Q filing, alongside typical clinical, regulatory and financing uncertainties.
Positive
- Preliminary net loss narrowed to $5.3 million for Q2 2026 from $11.2 million a year earlier, helped by substantially lower research and development spending.
- Cash and cash equivalents were $127.4 million as of March 31, 2026, and the company states this balance is expected to fund operations into mid‑to‑late fiscal 2028.
Negative
- Risk of Nasdaq non‑compliance due to failure to timely file the Form 10‑Q for the quarter ended March 31, 2026 and uncertainty around regaining compliance with Listing Rule 5250(c)(1).
Filing Explained
Reported financial figures remain subject to closing procedures and do not yet establish final second-quarter or six-month results.
As a Form 8-K, this filing reports the company’s preliminary financial results for the three and six months ended March 31, 2026, but completion of closing procedures could change them.
The results are furnished under Item 2.02, and the filing says they are not treated as filed for Section 18 liability or incorporated into future filings unless expressly stated.
For the six months, preliminary net loss was
At March 31, the preliminary balance sheet reported
8-K Event Classification
Key Figures
Key Terms
preliminary financial results financial
Nasdaq Listing Rule 5250(c)(1) regulatory
Fast Track designation regulatory
orphan drug designation medical
central nervous system (“CNS”) diseases medical
Earnings Snapshot
The company states it expects the cash balance at the end of the second fiscal quarter of 2026 to fund operations into mid‑to‑late fiscal 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) | |
|
|
|||
| (Address of Principal Executive Offices) | (Zip Code) | ||
Registrant’s
Telephone Number, Including Area Code: 1-
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 30, 2026, Anavex Life Sciences Corp. (the “Company”) issued a press release reporting preliminary financial results for its second quarter ended March 30, 2026 (the “Press Release”). The preliminary financial results in the Press Release are subject to completion of the Company’s financial closing procedures. Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The information furnished pursuant to Item 2.02. of this Current Report, including Exhibit 99.1 attached hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Cautionary Note Regarding Forward-Looking Statements
Statements in this Current Report on Form 8-K that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s preliminary financial results for the second quarter of fiscal 2026. These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, the risk that actual financial results may vary materially from the preliminary financial results presented in the Press Release and other the risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent filings and furnishings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update these statements to reflect events or circumstances after the date hereof except as required by law.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated July 30, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANAVEX LIFE SCIENCES CORP. | |||
| Date: | July 30, 2026 | By: | /s/ Sandra Boenisch |
| Sandra Boenisch, CPA, CGA Principal Financial Officer, Treasurer | |||
EXHIBIT 99.1
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease
New York, NY, July 30, 2026 - Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with high unmet medical needs, today reported preliminary financial results for its fiscal second quarter ended March 31, 2026. The Company’s primary focus is on advancing its lead compound ANAVEX®2-73 (blarcamesine) in the Company’s clinical program for the treatment of mild cognitive impairment (“MCI”) due to Alzheimer’s disease (“AD”) and mild AD (collectively known as “early AD”), and for Rett syndrome and Fragile X syndrome, both of which are neurodevelopmental rare diseases.
“Anavex remains firmly committed to our lead candidate oral blarcamesine (ANAVEX®2-73) for patients with Alzheimer’s disease, and we are prioritizing engagement with the U.S. FDA to align on a clear, data-driven regulatory and clinical development strategy,” stated Terrie Kellmeyer, PhD, Interim Chief Executive Officer. “A qualified data-driven approach will guide every decision we make. I have spent nearly three decades building and leading clinical and regulatory functions in drug development, and I’m bringing that experience to bear every day as we implement a disciplined regulatory strategy and build the right foundation for our programs. We are committed to advancing blarcamesine towards a clear regulatory path. I also want to recognize our employees, who have continued to show up for the patients who are counting on us, and the patients and families living with Alzheimer’s disease, Rett syndrome and Fragile X, who are depending on us to continue this important work on these urgent unmet medical needs. We are continuing to execute on the mission of developing targeted, orally delivered therapies for a specific range of CNS related diseases.”
Business Update & Anticipated Upcoming Milestones
| · | Anavex is prioritizing programs that the Company believes have the greatest potential for success. The strategy concentrates resources on blarcamesine across three CNS indications: early Alzheimer’s disease and Rett syndrome, where the Company’s clinical and regulatory foundation is most advanced, and Fragile X, where FDA Orphan Drug Designation, supportive preclinical and biomarker data, and the absence of any approved therapy may lead to a promising regulatory path with the FDA. |
Alzheimer’s Disease Program
| · | At the end of March 2026, the Company opened an Investigational New Drug (IND) application for early Alzheimer’s disease with the FDA. This is an important milestone: the IND enables clinical studies to be conducted in the U.S. and provides the basis for substantive discussions with the FDA to align on the Company’s future clinical development for early Alzheimer’s disease. |
| § | Two foundational clinical pharmacology studies are proceeding under this IND in the U.S.: an absorption, distribution, metabolism, and excretion (ADME) study and a drug-drug interaction (DDI) study with a goal to strengthen and support the Company’s regulatory pathway for all blarcamesine indications. |
| § | The Company anticipates initiation of the ADME study to take place in the third quarter of the 2026 calendar year, and dosing in the DDI study is already underway. |
| § | These studies are not sequential requirements. Rather, they support the overall FDA regulatory requirements for blarcamesine while the Company continues to advance its early Alzheimer’s disease program in parallel. |
| · | The Company intends to engage with the FDA on a U.S. clinical development strategy for early Alzheimer’s disease. The Company continues to review the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) assessment report and intends to use it to inform and support its clinical development strategy with the FDA. |
| · | In July 2026, Anavex attended the Alzheimer’s Association International Conference (AAIC) in London, England, which provided the Company with an opportunity to engage with clinicians, researchers and the broader Alzheimer’s community and to reinforce the Company’s continued commitment to bringing a treatment option to market for patients with early Alzheimer’s disease. |
Rett Syndrome Program
| · | The FDA has already granted Orphan Drug Designation, Rare Pediatric Disease (RPD) Designation and Fast Track Designation for blarcamesine in Rett syndrome. |
| § | The Company has aligned with the FDA on a Phase 3 clinical trial protocol for Rett syndrome for adults only. The Company intends to discuss with the FDA adding pediatric patients to the protocol, with a more detailed program update expected at a future date. |
Fragile X Syndrome Program
| · | The FDA has already granted Orphan Drug Designation for Fragile X syndrome. |
| § | The Company plans to initiate discussions with the FDA on the clinical development strategy for the Fragile X syndrome clinical program building on this designation, with further details to be shared as the program advances. |
Nasdaq Compliance
| · | On July 20, 2026, the Company submitted a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). |
Preliminary Fiscal Second Quarter 2026 Highlights
The financial results in this press release are preliminary and subject to completion of the Company’s financial closing procedures. Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026.
Preliminary cash and cash equivalents were $127.4 million as of March 31, 2026, compared to $102.6 million as of September 30, 2025. The Company expects the cash balance at the end of the second fiscal quarter of 2026 to fund operations into mid-to-late fiscal 2028.
Preliminary general and administrative expenses were $2.3 million for the second fiscal quarter of 2026 compared to $2.6 million for the second fiscal quarter of 2025. The decrease was primarily related to a decrease in legal and professional fees over the comparable period.
Preliminary research and development expenses were $4.2 million for the second fiscal quarter of 2026 compared to $9.9 million for the second fiscal quarter of 2025. The decrease was primarily attributable to the completion of the ANAVEX® 3-71 clinical trial for schizophrenia and a decrease in clinical manufacturing activities over the comparable period.
Preliminary Net loss for the second fiscal quarter of 2026 was $5.3 million, or $0.06 per share, compared to a net loss of $11.2 million, or $0.13 per share, for the second fiscal quarter of 2025.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system (“CNS”) diseases with high unmet medical need. Further information is available at www.anavex.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s preliminary financial results for the second quarter of 2026; the Company’s plans to prioritize engagement with the U.S. FDA to align on a clear, data-driven regulatory and clinical development strategy; the Company’s plans to continue to execute on its mission of developing targeted, orally delivered therapies for a specific range of CNS-related diseases; the timing, progress and results of advancement of ANAVEX®2-73 in clinical programs for the treatment of early Alzheimer’s, Rett syndrome and Fragile X syndrome; the Company’s plans to align with the FDA on a U.S. clinical development strategy for early Alzheimer’s disease, align on a Phase 3 protocol for Rett syndrome in both adult and pediatric patients, and align on a clinical development strategy for the Fragile X clinical program; and the Company’s expectations regarding its cash runway. These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s failure to timely file its Form 10-Q for the quarterly period ended March 31, 2026 and the Company’s ability to regain compliance with Nasdaq Listing Rule 5250(c)(1); that actual financial results may vary materially from the preliminary financial results presented in this press release; volatility in the Company’s stock price and the market in general; the Company’s ability to raise additional capital; Fast Track designation that the Company has received or may seek out may not actually lead to a faster FDA review and approval process; the Company may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity; undesirable side effects caused by the Company’s product candidates; the Company’s ability to attract and retain highly qualified personnel; the Company’s ability to obtain the support of qualified scientific collaborators; the Company’s reliance on third parties; the Company’s ability to obtain and maintain sufficient intellectual property protection for its product candidates; the Company’s ability to defend against claims of intellectual property infringement; the Company’s ability to compete in the highly competitive biotechnology and pharmaceutical industries; and other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent filings and furnishings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.
Investor Relations & Media Contact:
SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com
Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com
Company Contact:
Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email: ir@anavexcorp.com
| Anavex Life Sciences Corp. |
| Preliminary Condensed Consolidated Interim Statements of Operations and Comprehensive Loss1 |
| (in thousands, except share and per share amounts) |
| (Unaudited) |
| Three months ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating Expenses | ||||||||
| General and administrative | $ | 2,292 | $ | 2,621 | ||||
| Research and development | 4,192 | 9,892 | ||||||
| Total operating expenses | 6,484 | 12,513 | ||||||
| Operating loss | (6,484 | ) | (12,513 | ) | ||||
| Other income | ||||||||
| Research and development incentive income | 27 | 96 | ||||||
| Interest income, net | 1,061 | 1,210 | ||||||
| Foreign exchange gain (loss) | 58 | 11 | ||||||
| Total other income, net | 1,146 | 1,317 | ||||||
| Net loss before provision for income taxes | (5,338 | ) | (11,196 | ) | ||||
| Income tax expense, current | — | — | ||||||
| Net loss and comprehensive loss | $ | (5,338 | ) | $ | (11,196 | ) | ||
| Net loss per share | ||||||||
| Basic and diluted | $ | (0.06 | ) | $ | (0.13 | ) | ||
| Weighted average number of shares outstanding | ||||||||
| Basic and diluted | 92,675,753 | 85,073,769 | ||||||
[1] The financial results in this press release are preliminary and subject to completion of the Company’s financial closing procedures. Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026.
| Anavex Life Sciences Corp. |
| Preliminary Condensed Consolidated Interim Statements of Operations and Comprehensive Loss2 |
| (in thousands, except share and per share amounts) |
| (Unaudited) |
| Six months ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating Expenses | ||||||||
| General and administrative | $ | 4,417 | $ | 5,767 | ||||
| Research and development | 8,849 | 20,338 | ||||||
| Total operating expenses | 13,266 | 26,105 | ||||||
| Operating loss | (13,266 | ) | (26,105 | ) | ||||
| Other income | ||||||||
| Grant income | — | 12 | ||||||
| Research and development incentive income | 60 | 508 | ||||||
| Interest income, net | 2,140 | 2,604 | ||||||
| Foreign exchange gain (loss) | 65 | (326 | ) | |||||
| Total other income, net | 2,265 | 2,798 | ||||||
| Net loss before provision for income taxes | (11,001 | ) | (23,307 | ) | ||||
| Income tax expense, current | (18 | ) | — | |||||
| Net loss and comprehensive loss | $ | (11,019 | ) | $ | (23,307 | ) | ||
| Net loss per share | ||||||||
| Basic and diluted | $ | (0.12 | ) | $ | (0.27 | ) | ||
| Weighted average number of shares outstanding | ||||||||
| Basic and diluted | 90,832,571 | 84,938,400 | ||||||
[2] The financial results in this press release are preliminary and subject to completion of the Company’s financial closing procedures. Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026.
| Anavex Life Sciences Corp. | ||||||||
| Preliminary Condensed Consolidated Interim Balance Sheets[3] | ||||||||
| (in thousands, except share and per share amounts) (Unaudited) | ||||||||
| March 31, 2026 | September 30, 2025 | |||||||
| Assets | (unaudited) | |||||||
| Current | ||||||||
| Cash and cash equivalents | $ | 127,422 | $ | 102,577 | ||||
| Incentive and tax receivables | 932 | 809 | ||||||
| Prepaid expenses and other current assets | 412 | 429 | ||||||
| Total Assets | $ | 128,766 | $ | 103,815 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 2,520 | $ | 4,249 | ||||
| Accrued liabilities | 3,734 | 3,892 | ||||||
| Deferred grant income | 805 | 805 | ||||||
| Total Liabilities | 7,059 | 8,946 | ||||||
| Capital Stock | 93 | 87 | ||||||
| Additional paid-in capital | 515,081 | 477,230 | ||||||
| Accumulated deficit | (393,467 | ) | (382,448 | ) | ||||
| Total Stockholders’ Equity | 121,707 | 94,869 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 128,766 | $ | 103,815 | ||||
[3] The financial results in this press release are preliminary and subject to completion of the Company’s financial closing procedures. Actual results may vary materially from these preliminary financial results due to the completion of the Company’s financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company’s financial results for three and six months ended March 31, 2026.